It is no longer the current profile. Read the canonical profile and its correction notice.
We added a plain-language reader guide with cited answers, Phase 1 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 2 and Phase 3 trials. 256
What this version reported
The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.↗↗↗
Trial records: NCT07589686
Reader guide in this version
Key takeaway
Petrelintide, also known as ZP8396, is an experimental amylin analogue developed by Zealand Pharma with Roche, studied for weight management.1,2,3 It is not FDA-approved. Phase 3 trials sponsored by Roche were recruiting in late 2026, and none of the sources reviewed here reports an approval in any country.5,6 The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions and mostly mild gastrointestinal side effects.2
At a glance
- What it is
- An investigational amylin analogue, also known as ZP8396, from Zealand Pharma and Roche.1,2,3
- FDA status
- Not FDA-approved. Phase 3 trials, including ZUPREME-4 and ZUPREME-5, are registered on ClinicalTrials.gov.5,6
- Human evidence
- Two small randomized, placebo-controlled Phase 1 trials have published results. Phase 2 trials are listed as completed, but their results are not part of the sources cited here.2,3,4
- Evidence strength
- Smaller controlled human trials
What is petrelintide?
Petrelintide is an experimental amylin analogue also known by its development code, ZP8396.1,2
ClinicalTrials.gov lists Zealand Pharma as the sponsor of its Phase 2 trials and Hoffmann-La Roche as the sponsor of later trials, including a combination study with Zealand Pharma as collaborator.1,3,4
How is petrelintide thought to work?
Petrelintide is designed as an analogue of amylin, a hormone involved in appetite, and was studied in the Phase 1 trials for weight management.2
The published Phase 1 report studied its pharmacology and effects on body weight, but the sources reviewed here do not establish how it produces those effects in people.2
What do human studies show?
A published report describes two randomized, blinded, placebo-controlled Phase 1 trials. Earlier parts enrolled normal-weight or overweight adults, and a later part enrolled adults with overweight or obesity for 16 weeks.2
The report described weight reductions and no serious or severe adverse events that emerged during treatment. One participant stopped because of gastrointestinal events.2
These early trials were designed to assess safety and pharmacology, and their size and length cannot show long-term benefit or rule out uncommon harms.2
What the evidence base contains
- Controlled human trial Two randomized, blinded, placebo-controlled Phase 1 trials, one following participants for 16 weeks, in normal-weight, overweight or obese adults. The published abstract does not give total enrollment.2
- Registered trial without results ZUPREME (NCT06662539), a Phase 2 obesity trial, and a Phase 2 trial in overweight or obesity with type 2 diabetes (NCT06926842), both sponsored by Zealand Pharma and listed as completed in their 2026 registry records.3,4
- Registered trial without results ZUPREME-5 (NCT07843472) and ZUPREME-4 (NCT07843485), Phase 3 trials sponsored by Roche and listed as recruiting in their October and November 2026 registry records.5,6
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Is petrelintide FDA-approved?
No. Petrelintide remains in clinical trials. None of the sources reviewed here reports an approval of petrelintide in any country.2,5,6
As of their retained registry records, ZUPREME-5 (October 7, 2026) and ZUPREME-4 (November 5, 2026), Phase 3 trials sponsored by Roche, were listed as recruiting.5,6
A Phase 2 combination study with enicepatide, sponsored by Roche, was listed as not yet recruiting in its July 7, 2026 record.1
Timeline
- Results of two randomized Phase 1 trials of petrelintide are published.2
- ClinicalTrials.gov lists the ZUPREME Phase 2 obesity trial as completed.3
- ClinicalTrials.gov lists a Phase 2 trial in overweight or obesity with type 2 diabetes as completed.4
- The retained ClinicalTrials.gov record of the ZUPREME-5 Phase 3 trial lists it as recruiting.5
- The retained ClinicalTrials.gov record of the ZUPREME-4 Phase 3 trial lists it as recruiting.6
What is still unknown?
What the completed Phase 2 trials found: their results are not part of the sources cited here.3,4
Its effects and safety in larger, longer trials, which the Phase 3 program is registered to study.5,6
Sources for this version
- 1Petrelintide With Enicepatide in Adults With Obesity or Overweight · record history version 3 · last update posted 2026-07-07 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials (2026) · PMID 42017294 ↗
Diabetes, Obesity and Metabolism · Official source · Source checked November 14, 2026
- 3ClinicalTrials.gov record NCT06662539 · retained source version 2026-03-23:25a9d8533efb66766440e5abf5b03342f70235dae33ae71a773e757bb8847402 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 4ClinicalTrials.gov record NCT06926842 · retained source version 2026-09-09:66566db76c0ba35707f571957d43a26bb1a34c1cb277263d2109ca1fdebaf137 ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 5ClinicalTrials.gov record NCT07843472 · retained source version 2026-10-07:b4d7f3eecf4b6c9a8842198319f5d5c3a421bf03ca09434d4d315fdacfc97697 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026
- 6ClinicalTrials.gov record NCT07843485 · retained source version 2026-11-05:e5fd0540362d59efc4e0e476ab3f05c74427735d5576cee67cbafed4c6f394d5 ↗
ClinicalTrials.gov · Official source · Source checked November 14, 2026